CRSP Latest Headlines

Crispr Therapeutics Updates CTX131 Cancer Trial: What Investors Need to Know

at www.tipranks.com (Thu, 5-Nov 11:30 AM)

CRISPR Therapeutics tees up an ASH oral presentation on zugo-cel’s dose-dependent efficacy in refractory large B-cell lymphoma

Market Chameleon (Wed, 4-Nov 9:36 AM)

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), IDEAYA Biosciences (IDYA) and Rhythm Pharmaceuticals (RYTM)

at www.tipranks.com (Wed, 4-Nov 8:30 AM)

Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Crispr Therapeutics AG (CRSP) and Amgen (AMGN)

at www.tipranks.com (Wed, 4-Nov 5:10 AM)

Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital

at www.tipranks.com (Tue, 3-Nov 8:45 PM)

Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH)

at www.tipranks.com (Tue, 3-Nov 1:30 PM)

Crispr Therapeutics AG (CRSP) Receives a Rating Update from a Top Analyst

at www.tipranks.com (Tue, 3-Nov 8:04 AM)

Crispr Therapeutics AG (CRSP) Receives a Buy from Piper Sandler

at www.tipranks.com (Tue, 3-Nov 7:56 AM)

CRISPR Therapeutics’ Growing Casgevy Adoption and Near-Term Pipeline Catalysts Support a Buy Rating

at www.tipranks.com (Tue, 3-Nov 7:47 AM)

CRISPR Therapeutics taps a manufacturing veteran as CTO as it pushes gene editing and RNA programs toward late-stage development

Market Chameleon (Mon, 2-Nov 8:22 AM)

CRISPR Therapeutics GAAP EPS of -$1.15 misses by $0.15, revenue of $12.67M misses by $3.89M

at seekingalpha.com (Mon, 2-Nov 4:03 PM)

CRISPR Therapeutics Names A.J. Silver CFO as Raju Prasad Steps Down, Effective Today

Market Chameleon (Tue, 20-Oct 8:43 AM)

CRISPR Therapeutics Puts CTX310 Phase 1b Severe Hypertriglyceridemia Data on the AHA 2026 Late-Breaking Stage

Market Chameleon (Fri, 9-Oct 11:27 AM)

CRISPR Therapeutics targets an AHA 2026 spotlight with late-breaking Phase 1b CTX310 data in severe hypertriglyceridemia

Market Chameleon (Thu, 8-Oct 8:45 AM)